Sandow J

No ORCID on file · 12 papers in corpus · active 1983-1992

Study types

  • article 7
  • other 3
  • review 2

Condition tags

  • endometriosis 11
article 1992
Clinical endocrinology ·doi:10.1111/j.1365-2265.1992.tb02908.x

OBJECTIVE: The duration of action of a gonadotrophin releasing hormone (GnRH) agonist implant designed to be effective for 3 months was investigated in women by monitoring drug release and ovarian hormone secretion. Serum inhibin secretion …

article 1990
Fertility and Sterility ·doi:10.1016/s0015-0282(16)53217-8

Ten endometriosis patients received luteinizing hormone releasing hormone (LH-RH) agonist (buserelin) implant injections (6.6 mg subcutaneously) at days 0, 42, 84 and 126. Serum LH and follicle-stimulating hormone (FSH) were lowered by day …

other 1990
The Journal of steroid biochemistry and molecular biology ·doi:10.1016/0960-0760(90)90445-q

The LHRH agonists are antigonadotropic agents for reversible ovarian suppression in gynaecology and in oncology. In oncology, pituitary inhibition is maintained with high release rates preferably by implant or microcapsule injection. The ph…

other 1989
Fertility and Sterility ·doi:10.1016/s0015-0282(16)60783-5

One hundred infertile patients with laparoscopically confirmed ovarian endometriosis were treated with either intranasal (IN) Buserelin (Hoechst, AG, Frankfurt am Main, West Germany) (300 micrograms three times a day) or subcutaneous (SC) B…

article 1989
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jcem-68-6-1167

We studied the pharmacokinetics of iv and intranasally administered buserelin, a LHRH agonist peptide, in 14 women with endometriosis. Serum and urinary buserelin concentrations were determined by specific RIA (buserelin antiserum AS-639). …

article 1988
Fertility and Sterility ·doi:10.1016/s0015-0282(16)59887-2

In order to suppress the pituitary-ovarian axis for treatment of endometriosis, the luteinizing hormone-releasing hormone (LH-RH) agonist buserelin (Hoechst Canada Inc., Montreal, Quebec, Canada) was administered by continuous subcutaneous …

article 1988
Fertility and Sterility ·doi:10.1016/s0015-0282(16)59764-7

Six endometriosis patients were treated with continuous subcutaneous (SC) infusion of a luteinizing hormone-releasing hormone (LH-RH) agonist using an external osmotic minipump system. Serum estradiol (E2) was suppressed into the menopausal…

review 1986
Progress in clinical and biological research
article 1986
Progress in clinical and biological research
article 1985
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jcem-60-3-579

The effect of continuous administration of an LHRH agonist for 14 days on follicular estradiol secretion was studied in adult female stumptailed macaque monkeys. The infusion was started either during the early follicular phase or during th…

other 1985
Der Internist
review 1983
Clinical endocrinology ·doi:10.1111/j.1365-2265.1983.tb00595.x

The physiological requirement for activation of pituitary gonadotrophin secretion by pulsatile LHRH stimulation is discussed, and compared with the effect of pituitary stimulation by LHRH agonists. Initial stimulation is followed by a phase…